Efficacy and safety of immune checkpoint inhibitors in advanced or recurrent endometrial cancer: individual patient data and trial-level meta-analysis
Objective Whether immune checkpoint inhibitor (ICI)-based regimens confer a survival benefit over chemotherapy (CT) alone in advanced/recurrent endometrial cancer (EC), particularly by mismatch repair status, remains inconclusive. We conducted an individual patient data (IPD) meta-analysis of randomized trials comparing ICI-based regimens vs. CT alone to quantify survival benefits and assess safety.
Authors
- Fengping Shao (ORCID: https://orcid.org/0000-0002-3768-2389)
- Yanchun Liang (ORCID: https://orcid.org/0000-0001-7756-1621)
Institutions
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3802/jgo.2027.38.e46
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province
- National Key Research and Development Program of China